Anthropic Raises $65 Bn in Funding, Reaches $965 Bn Valuation
Advertisement
The funding also includes $15 billion of previously committed investments, including $5 billion from the global technology and cloud service company Amazon.
US-based Anthropic has raised $ 65 billion in Series H funding led by Altimeter Capital, Dragoneer, Greenoaks, and Sequoia Capital.
The new funding has brought the company’s valuation to $965 billion, surpassing that of OpenAI and making it one of the world's most valuable private AI companies.
The latest funding is expected to advance the safety and interpretability research, expand computing infrastructure to meet growing demand for its Claude AI platform, and support the scaling of enterprise products and strategic partnerships.
Reportedly, the funding also includes $15 billion of previously committed investments, including $5 billion from the global technology and cloud service company Amazon.
The latest Series H round comes three months after the company raised $30 billion in Series G funding.
In addition, the company also announced that strategic infrastructure partners joined the investor group, including Micron, Samsung, and SK Hynix, which offer technologies such as memory, storage, and logic chips required for large-scale AI deployment.
Commenting on the latest investment, Brad Gerstner, Founder and CEO of Altimeter Capital, said, “Claude’s latest advancements have driven large-scale adoption among the world’s most demanding organizations. This momentum positions Anthropic to lead the next phase of AI innovation and capture the enormous opportunity ahead.”
The funding follows a series of enterprise-focused initiatives by Anthropic.
Earlier this year, the company launched Claude for Healthcare enterprises, a new set of artificial intelligence tools built on the Claude Opus 4.5 model.
It is designed to support enterprise healthcare workflows involving protected health information, offering HIPAA-ready infrastructure, healthcare-trained models, and native connections to widely used medical and scientific databases.
Days back, the company announced an enterprise-wide deal with Bristol Myers Squibb to deploy Claude throughout the pharma giant's research, manufacturing, corporate, clinical development, and commercial functions.
The deployment focuses on implementing Claude Code within engineering and data science teams for AI and software development, embedding agents into workflows and connecting Claude to BMS's "institutional knowledge."
In another major initiative, the tech giant had announced a four-year partnership with the Gates Foundation worth $200 million to expand the use of artificial intelligence in healthcare and education, with a focus on improving access and outcomes in underserved regions.
Stay tuned for more such updates on Digital Health News
